BLINCYTO 38.5mcg powder for concentrate and solution for infusion AMGEN ORIGINAL MEDICINE
Chemical substance: blinatumomab
Active substance
Results for the substance blinatumomab
1 result
About this active substance
Blinatumomab is a monoclonal antibody used for the treatment of B-cell acute lymphoblastic leukemia (ALL), particularly in patients with relapsed or refractory disease. It is an immunotherapeutic agent that activates T-cells in the immune system to attack cancer cells.
The medication is administered via continuous intravenous infusion, usually over several weeks, according to a strict protocol established by the doctor. The treatment requires close monitoring in the hospital, especially during the initial days.
Common side effects include fever, headache, nausea, fatigue, and a decrease in blood cell counts. In rare cases, severe adverse effects such as cytokine release syndrome or neurotoxicity may occur.
Blinatumomab is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor of their full medical history and any other medications being used before starting treatment.
The medication is administered via continuous intravenous infusion, usually over several weeks, according to a strict protocol established by the doctor. The treatment requires close monitoring in the hospital, especially during the initial days.
Common side effects include fever, headache, nausea, fatigue, and a decrease in blood cell counts. In rare cases, severe adverse effects such as cytokine release syndrome or neurotoxicity may occur.
Blinatumomab is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor of their full medical history and any other medications being used before starting treatment.